Prognostic Factors in Patients With Advanced Pancreatic Adenocarcinoma Treated With Intra-Arterial Chemotherapy

Objectives: The aim of this study is to identify the prognostic factors of a large group of patients with pancreatic cancer who underwent the same regimen of intra-arterial chemotherapy. Methods: 5-Fluorouracil (1000 mg/m2), leucovorin (100 mg/m2), epirubicin (60 mg/m2), and carboplatin (300 mg/m2) were administered every 3 weeks into celiac axis (FLEC regimen). Kaplan-Meyer survival curve for univariate analysis and Cox regression model for multivariate one were used to determine factors predictive of survival. Results: Data of 211 patients with advanced pancreatic cancer who underwent FLEC regimen were analyzed. Eighty-nine had locally advanced disease, and 112 had distant metastases. Median overall survival was 9.2 months. In both univariate and multivariate analyses, pain reduction after treatment (≤30% of baseline level vs >30%; overall survival, 7.6 vs 11.5 months), stage of disease (III vs IV; overall survival, 10.5 vs 6.6 months), and number of administered cycles (≤3 vs >3; overall survival, 5.9 vs 12.3 months) were significant and independent predictors of survival. Conclusions: Pain reduction, stage of disease, and number of administered cycles are independent prognostic factors of overall survival in a multivariate analysis of patients with advanced pancreatic cancer receiving FLEC regimen intra-arterially.

[1]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[2]  H. Ueno,et al.  Abdominal Pain in Patients with Resectable Pancreatic Cancer with Reference to Clinicopathologic Findings , 2001, Pancreas.

[3]  J. Kench,et al.  Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. , 2001, Cancer research.

[4]  M. O’connell.  A phase III trial of 5‐fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A mayo clinic/north central cancer treatment group study , 1989, Cancer.

[5]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[6]  S. Alıcı,et al.  Prognostic Factors in Pancreatic Carcinoma: Serum LDH Levels Predict Survival in Metastatic Disease , 2001, American journal of clinical oncology.

[7]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Schmiegel,et al.  Recent Discoveries in Cancer Genetics of Exocrine Pancreatic Neoplasia , 1998, Digestion.

[9]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[10]  T. Oda,et al.  Onset Symptoms and Tumor Locations as Prognostic Factors of Pancreatic Cancer , 2004, Pancreas.

[11]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[12]  E. Casper,et al.  Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas , 2004, Investigational New Drugs.

[13]  M. Marangolo,et al.  Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. , 2004, Journal of chemotherapy.

[14]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[16]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[17]  P. Rissanen,et al.  Operative finding, treatment, and prognosis of carcinoma of the pancreas: An analysis of 267 cases , 1983, Journal of surgical oncology.

[18]  W. Scheithauer,et al.  Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) , 2005 .

[19]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[20]  P. Pederzoli,et al.  Intra-arterial chemotherapy for unresectable pancreatic cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  H. Wieand,et al.  Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Imamura,et al.  Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. , 1998, European journal of cancer.

[23]  C. Compton,et al.  Prognostic factors in pancreatic carcinoma. , 1997, Surgical oncology clinics of North America.

[24]  J. Klempnauer,et al.  Back pain in patients with ductal pancreatic cancer. Its impact on resectability and prognosis after resection. , 1995, Scandinavian journal of gastroenterology.

[25]  M. Yashiro,et al.  Prognostic value of microsatellite instability in resectable pancreatic cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  H. Ueno,et al.  Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy , 2001, Cancer.